{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:05:02Z","timestamp":1793642702820,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10871-9","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:55:04Z","timestamp":1752137704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MISHTI study evaluating hepatic fibrosis in type 2 diabetes patients in India"],"prefix":"10.1038","volume":"15","author":[{"given":"Debasis","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna G.","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samit","family":"Ghosal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"10871_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","volume":"122","author":"V Lekakis","year":"2024","unstructured":"Lekakis, V. & Papatheodoridis, G. V. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur. J. Intern. Med. 122, 3\u201310 (2024).","journal-title":"Eur. J. Intern. Med."},{"issue":"2","key":"10871_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/ueg2.12508","volume":"12","author":"L Otero Sanchez","year":"2024","unstructured":"Otero Sanchez, L., Chen, Y., Lassailly, G. & Qi, X. Exploring the links between types two diabetes and liver-related complications: A comprehensive review. United Eur. Gastroenterol. J. 12 (2), 240\u2013251 (2024).","journal-title":"United Eur. Gastroenterol. J."},{"issue":"9","key":"10871_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7 (9), 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10871_CR4","doi-asserted-by":"publisher","first-page":"22232","DOI":"10.1038\/s41598-024-72795-0","volume":"14","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021. Sci. Rep. 14 (1), 22232 (2024).","journal-title":"Sci. Rep."},{"issue":"10","key":"10871_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 22 (10), 1999\u20132010 (2024). e8.","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10871_CR6","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1111\/liv.16016","volume":"44","author":"DR Riley","year":"2024","unstructured":"Riley, D. R. et al. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 44 (10), 2538\u20132550 (2024).","journal-title":"Liver Int."},{"issue":"12","key":"10871_CR7","doi-asserted-by":"publisher","first-page":"e34809","DOI":"10.2196\/34809","volume":"8","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. The global, regional, and National burden and trends of NAFLD in 204 countries and territories: an analysis from global burden of disease 2019. JMIR Public. Health Surveill. 8 (12), e34809 (2022).","journal-title":"JMIR Public. Health Surveill"},{"issue":"4","key":"10871_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jhep.2018.07.020","volume":"69","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. & Pageaux, G. P. A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! J. Hepatol. 69 (4), 767\u2013768 (2018).","journal-title":"J. Hepatol."},{"issue":"6","key":"10871_CR9","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell, P. B. et al. American heart association Council on arteriosclerosis, thrombosis and vascular biology; Council on hypertension; Council on the kidney in cardiovascular disease; Council on lifestyle and cardiometabolic health; and Council on peripheral vascular disease. Nonalcoholic fatty liver disease.and cardiovascular risk: A scientific statement from the American heart association. Arterioscler. Thromb. Vasc Biol. 42 (6), e168\u2013e185 (2022).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"5","key":"10871_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MEG.0000000000002741","volume":"36","author":"TH Shen","year":"2024","unstructured":"Shen, T. H., Wu, C. H., Lee, Y. W. & Chang, C. C. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12\u201379 years. Eur. J. Gastroenterol. Hepatol. 36 (5), 636\u2013645 (2024).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"6","key":"10871_CR11","first-page":"1377","volume":"11","author":"Q Binet","year":"2023","unstructured":"Binet, Q., Loumaye, A., Hermans, M. P. & Lanthier, N. A Cross-sectional Real-life study of the prevalence, severity, and determinants of metabolic Dysfunction-associated fatty liver disease in type 2 diabetes patients. J. Clin. Transl Hepatol. 11 (6), 1377\u20131386 (2023).","journal-title":"J. Clin. Transl Hepatol."},{"issue":"4","key":"10871_CR12","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/j.jhep.2024.05.027","volume":"81","author":"A De","year":"2024","unstructured":"De, A., Mehta, M., Duseja, A. & ICOM-D study group. Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: an analysis of the Indian consortium on MASLD (ICOM-D) cohort. J. Hepatol. 81 (4), e162\u2013e164 (2024).","journal-title":"J. Hepatol."},{"issue":"6","key":"10871_CR13","first-page":"e62405","volume":"16","author":"A Naskar","year":"2024","unstructured":"Naskar, A., Mondal, A., Chatterjee, R., De, R. D. & Roy, S. Assessing liver fibrosis in type 2 diabetes mellitus patients with metabolic Dysfunction-Associated steatotic liver disease: the role of Non-invasive scoring systems and associated factors. Cureus 16 (6), e62405 (2024).","journal-title":"Cureus"},{"key":"10871_CR14","unstructured":"American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. ;48(Supplement_1):S59-S85. (2025)."},{"issue":"5","key":"10871_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156 (5), 1264\u20131281e4 (2019).","journal-title":"Gastroenterology"},{"issue":"2","key":"10871_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco, R. et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 44 (2), 399\u2013406 (2021).","journal-title":"Diabetes Care"},{"issue":"5","key":"10871_CR17","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.aohep.2024.101516","volume":"29","author":"M Li","year":"2024","unstructured":"Li, M. et al. The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB 4 score in screening the population for liver disease. Ann. Hepatol. 29 (5), 101516 (2024).","journal-title":"Ann. Hepatol."},{"issue":"1","key":"10871_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo, P. Y., Cohen, S. M. & Lim, J. K. ACG clinical guideline: evaluation of abnormal liver chemistries. Am. J. Gastroenterol. 112 (1), 18\u201335 (2017).","journal-title":"Am. J. Gastroenterol."},{"issue":"Supplement_1","key":"10871_CR19","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in Diabetes-2025. Diabetes Care. 48 (Supplement_1), S27\u2013S49 (2025).","journal-title":"Diabetes Care"},{"issue":"3","key":"10871_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL). European association for the study of diabetes (EASD); European association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81 (3), 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"issue":"3","key":"10871_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","volume":"12","author":"EA Shalimar","year":"2022","unstructured":"Shalimar, E. A. et al. Prevalence of Non-alcoholic fatty liver disease in india: A systematic review and Meta-analysis. J. Clin. Exp. Hepatol. 12 (3), 818\u2013829 (2022).","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"7","key":"10871_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.59556\/japi.72.0582","volume":"72","author":"V Panikar","year":"2024","unstructured":"Panikar, V. et al. Prevalence and association of risk factors according to liver steatosis and fibrosis stages among nonalcoholic fatty liver disease patients with type 2 diabetes mellitus in india: A Cross-sectional study. J. Assoc. Physicians India. 72 (7), 29\u201333 (2024).","journal-title":"J. Assoc. Physicians India"},{"issue":"11","key":"10871_CR23","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","volume":"20","author":"I Graupera","year":"2022","unstructured":"Graupera, I. et al. Investigators of the liverscreen consortium. Low accuracy of FIB 4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin. Gastroenterol. Hepatol. 20 (11), 2567\u20132576 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10871_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","volume":"167","author":"LA van Kleef","year":"2024","unstructured":"van Kleef, L. A. et al. Metabolic dysfunction-Associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology 167 (2), 357\u2013367e9 (2024).","journal-title":"Gastroenterology"},{"issue":"3","key":"10871_CR25","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/dom.16109","volume":"27","author":"M Li","year":"2025","unstructured":"Li, M. et al. The fibrosis investigating navigator in diabetes (FIND): A tool to predict liver fibrosis risk in subjects with diabetes. Diabetes Obes. Metab. 27 (3), 1184\u20131197 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"10871_CR26","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive Tests for Evaluation of Liver Disease Severity and Prognosis \u2013\u20092021 Update. J. Hepatol."},{"issue":"5","key":"10871_CR27","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77 (5), 1797\u20131835 (2023).","journal-title":"Hepatology"},{"issue":"3","key":"10871_CR28","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos, A. S. et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 74 (3), 1220\u20131233 (2021).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10871-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:30:43Z","timestamp":1757215843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10871-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10871"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10871-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6224000\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"MSPL-MASLD-001 & version-1.0. Approving centre: INDIRA IVF hospital Institutional Ethics Committee. Reg No. ECR\/1627\/Inst\/WB\/2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical committee approval"}}],"article-number":"24772"}}